Recent advances in understanding the pathophysiology of multiple sclerosis (MS) have made possible the development of exciting new treatment options. This nine-part virtual grand rounds series explores a number of important issues, illustrated by patient examples encountered in daily practice.
Covered topics include the process of neural damage and the possibility that available and emerging agents may have a role in neuronal preservation; the latest data on current and emerging oral small molecules and monoclonal antibodies; the rationale for early diagnosis and intervention, criteria for evaluating response, and approaches to managing suboptimal response; optimizing the use of available agents in more aggressive regimens and possible drug combinations; managing walking impairment and neurogenic bladder dysfunction; balancing disease-modifying therapy and symptomatic therapy; managing breakthrough disease; and new and emerging therapies: is it time to change the status quo?


